HOVON HO180 CLL
Planned
Main info
- Identifier:
- HO180 CLL-ODYSSEUS
- Sponsor:
- HOVON
- Working group party:
- CLL
- Stage:
- 2nd Line
- Echelon:
- Level D
- Active sites:
-
0(of 1)17 sites are pending
- Title:
Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
Timeline
Scheduled
Actual
2023
04 Jul
Opportunity
2025
01 Oct
Development
2025
17 Dec
Development
2026
25 Feb
Submission in Progress
2026
14 Aug
EC Approval
2026
01 Sep
First Site
2026
01 Sep
Activated
2026
15 Sep
FPI
2028
01 Sep
ClosedForInclusionScheduledStart
2030
30 Nov
Endpoint Analysis
2032
01 Sep
CloseoutInProgressLastPtOutScheduledStart
2033
01 Sep
Archived
News
17Dec2025: internal Kick-off meeting
Details
- Phase:
- Prospective Phase II study
- Monitoring Type:
- HOVON Monitoring Visit
- Objectives:
Participating Sites
Site
17 results
Order by
Accrual rate
Activation date
NL-Amsterdam-OLVG
SE-Örebro-OREBROUH
SE-Lund-SUH
NL-Doetinchem-SLINGELAND
NL-Rotterdam-IKAZIA
NL-Groningen-MARTINI
NL-Almere-FLEVOZIEKENHUIS
NL-Amsterdam-AMSTERDAMUMC
DK-Copenhagen-RIGSHOSPITALET
NL-Dordrecht-ASZ
NL-Hoofddorp-SPAARNEGASTHUIS
NL-Eindhoven-MAXIMAMC
NL-Rotterdam-MAASSTADZIEKENHUIS
NL-Nieuwegein-ANTONIUS
NL-Den Haag-HMCWESTEINDE
NL-Breda-AMPHIA
NL-Leeuwarden-FRISIUSMC
= Active hospitals 
= Inactive hospitals